Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV
Bakani Butale
A * , Ian Woolley A B , Kathryn Cisera B , Tony Korman A B and Georgia Soldatos C
A Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic., Australia.
B Monash Infectious Diseases, Monash Health, Melbourne, Vic., Australia.
C Monash Diabetes and Vascular Medicine Unit, Monash Health, Melbourne, Vic., Australia.
Sexual Health 19(6) 580-582 https://doi.org/10.1071/SH22070
Submitted: 19 April 2022 Accepted: 29 July 2022 Published: 23 August 2022
© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing
Abstract
Diabetes is an increasingly common co-morbidity in people living with HIV (PLWH). Given new evidence demonstrating cardiovascular benefits of sodium glucose transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) in diabetic patients, we reviewed medical charts of 262 PLWH at Monash Health through a 1-year retrospective cohort study to determine the rates of their use. Prevalence of diabetes was 13.4% (35) and 60% (21) had microvascular and macrovascular complications. Only 4% (95% CI 0.1%–19.6%) of diabetic patients were receiving SGLT2i and 19% (95% CI 6%–39.4%) were receiving GLP1RA. Prescribers should carefully consider their choice of glucose-lowering medication when treating PLWH.
Keywords: cardiovascular, diabetes, evidence-based medicine, GLP1RA, glucose-lowering medications, HIV co-morbidities, HIV/AIDS, SLGT2i.
References
[1] Paik IJ, Kotler DP. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 2011; 25 469–78.| The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection.Crossref | GoogleScholarGoogle Scholar |
[2] Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373 2117–28.
| Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.Crossref | GoogleScholarGoogle Scholar |
[3] Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375 311–22.
| Liraglutide and cardiovascular outcomes in type 2 diabetes.Crossref | GoogleScholarGoogle Scholar |
[4] Mahtta D, Ramsey DJ, Lee MT, Chen L, Al Rifai M, Akeroyd JM, et al. Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs. Diabetes Care 2022; 45 372–80.
| Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs.Crossref | GoogleScholarGoogle Scholar |
[5] García de Lucas MD, Olalla J. Experience of using ISGTL-2 in patients with DM2 and HIV infection. Eur J Intern Med 2017; 41 e29
| Experience of using ISGTL-2 in patients with DM2 and HIV infection.Crossref | GoogleScholarGoogle Scholar |
[6] Diamant M, van Agtmael M. Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes. Diabetes Care 2012; 35 e34
| Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes.Crossref | GoogleScholarGoogle Scholar |
